Buy Like Buffett
Watchlist

Flagship explainer

How Orchestra BioMed Holdings, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$33.5M · 100%Cost of revenue$190000 · 1%Gross profit$33.3M · 99%Operating income−$51.8M · −155%Income before tax−$52.7M · −157%Income tax$0 · 0%Net income−$52.7M · −157%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$33.5M100%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
Cost of revenue$1900001%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
$33.3M99%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
−$51.8M−155%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
Income before tax−$52.7M−157%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
Income tax$00%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
−$52.7M−157%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-026754 · filed Mar 12, 2026
· event Dec 31, 2025 · retrieved Sep 19, 2026 · annual-row source set
Embed this chart

View the full Orchestra BioMed Holdings, Inc. analysis at Buy Like Buffett